Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Autor: Öcal, Osman, Schinner, Regina, Schütte, Kerstin, de Toni, Enrico N., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J., Sengel, Christian, Bargellini, Irene, Gasbarrini, Antonio, Sangro, Bruno, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max, Kettner, E., Amthauer, H., Cwikla, J., Walecki, J., Klümpen, H., Schott, E., Kolligs, F., Rosmorduc, O., Menu, Y., Leroy, V., Mayerle, J., Trumm, C., Bartenstein, P., Reiser, M., Berg, T., Moche, M., Bilbao, I., Gossner, L., Reimer, P., Popovic, P., Stabuc, B., Piasecki, P., Podgajny, Z., Sacco, R., Peck-Radosavljevic, M., Lammer, J., Maleux, G., Verslype, C., Rosenberg, C., Nitsche, D., Waldenberger, P., Vergniol, J., Cassinotto, C., Yalcin, S., Peynircioglu, B., Zavaglia, C., Rampoldi, A., Tran, A., Chevallier, P., Anty, R., Trautwein, C., Kuhl, C., Grazioli, L., Vogl, T., Trojan, J., Bartolozzi, C., Iezzi, R., Bronowicki, J. P., Palmer, D., Evans, J., Sharma, R., Weir, G., Hubner, R., Basu, B., Ross, P.

Publikováno v: Cancer Imaging, Vol 22, Iss 1, Pp 1-13 (2022)
Cancer imaging, 22(1):1. BioMed Central Ltd.
Öcal, O, Schinner, R, Schütte, K, de Toni, E N, Loewe, C, van Delden, O, Vandecaveye, V, Gebauer, B, Zech, C J, Sengel, C, Bargellini, I, Gasbarrini, A, Sangro, B, Pech, M, Malfertheiner, P, Ricke, J, Seidensticker, M, SORAMIC study group, Kettner, E, Amthauer, H, Cwikla, J, Walecki, J, Klümpen, H, Schott, E, Kolligs, F, Rosmorduc, O, Menu, Y, Leroy, V, Mayerle, J, Trumm, C, Bartenstein, P, Reiser, M, Berg, T, Moche, M, Bilbao, I, Gossner, L, Reimer, P, Popovic, P, Stabuc, B, Piasecki, P, Podgajny, Z, Sacco, R, Peck-Radosavljevic, M, Lammer, J, Maleux, G, Verslype, C, Rosenberg, C, Nitsche, D, Waldenberger, P, Vergniol, J, Cassinotto, C, Yalcin, S, Peynircioglu, B, Zavaglia, C, Rampoldi, A, Tran, A, Chevallier, P, Anty, R, Trautwein, C, Kuhl, C, Grazioli, L, Vogl, T, Trojan, J, Bartolozzi, C, Iezzi, R, Bronowicki, J P, Palmer, D, Evans, J, Sharma, R, Weir, G, Hubner, R, Basu, B & Ross, P 2022, ' Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib ', Cancer imaging, vol. 22, no. 1, 1 . https://doi.org/10.1186/s40644-021-00439-x
Cancer Imaging
Cancer imaging 22, 1 (2022). doi:10.1186/s40644-021-00439-x
Cancer imaging, 22(1):1. e-med

Cancer imaging 22, 1 (2022). doi:10.1186/s40644-021-00439-x
Published by BioMed Central, London

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4729d698b2dfd43c9c1a684f537d6364

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: A single-center experience

Autor: Mazzarelli, C., Costantino, D., Cesarini, L., Zavaglia, C., Rampoldi, A., Morelli, F., Cabrini, G., Capitanio, S., Zanni, D., Carboni, C., Belli, L.S.

Publikováno v: In Digestive and Liver Disease March 2023 55 Supplement 1:S68-S68

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response toα-interferon treatment in patients with chronic hepatitis C.

Autor: Airoldi, A.¹, Zavaglia, C.¹ epatogastro@ospedaleniguarda.it, Silini, E.², Tinelli, C.³, Martinetti, M.⁴, Asti, M.⁴, Rossini, A.⁵, Vangeli, M.¹, Salvaneschi, L.⁴, Pinzello, G.¹

Publikováno v: European Journal of Immunogenetics. Dec2004, Vol. 31 Issue 6, p259-265. 7p.

Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival

Autor: Mazza, S., Invernizzi, F., Iavarone, M., Zavaglia, C., Maggi, U., Cesarini, L., Antonelli, B., Airoldi, A., Manini, M.A., Sangiovanni, A., Rossi, G., Donato, M.F., Belli, L.S., Lampertico, P.

Publikováno v: In Digestive and Liver Disease February 2019 51 Supplement 1:e35-e35